Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | IMO-2125 plus ipilimumab for anti-PD-1 refractory melanoma: ILLUMINATE-301

Paolo Ascierto • 22 Oct 2018
ESMO 2018
Melanoma Skin Cancer IMO-2125 Ipilimumab
ILLUMINATE-301

Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, gives us an update on the ongoing Phase III ILLUMINATE-301 trial (NCT03445533) in anti-PD1 refractory melanoma, which is comparing the combination of the TLR9 agonist IMO-2125 with the CTLA-4 checkpoint inhibitor ipilimumab vs. ipilimumab alone.

More from Paolo Ascierto

What is the importance of CTLA-4 inhibition in treating melanoma?
1:05
What is the importance of CTLA-4 inhibition in treating melanoma?
Paolo Ascierto • 20 Oct 2025
CheckMate 238: 9-year outcomes of adjuvant nivolumab vs ipilimumab in melanoma
2:55
CheckMate 238: 9-year outcomes of adjuvant nivolumab vs ipilimumab in melanoma
Paolo Ascierto • 20 Oct 2025
Phase II trial of BNT111 and cemiplimab in PD-1–refractory melanoma
2:31
Phase II trial of BNT111 and cemiplimab in PD-1–refractory melanoma
Paolo Ascierto • 20 Oct 2025
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma
2:03
7-y results from CheckMate 238: adjuvant NIVO vs IPI in resected stage III/IV melanoma
Paolo Ascierto • 21 Oct 2023

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals